Company intelligence / Profile preview

Leal Therapeutics

Worcester, Massachusetts, United Stateslealtx.com ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Lead programs LTX-002 and LTX-001 are on track for IND applications by the end of 2024, with clinical trials expected to begin in early 2025. The company recently secured $45 million in financing to advance these programs.

Therapeutic areas: PsychiatryOphthalmologyNeurology
Modalities: Antisense oligonucleotides (ASOs)Small molecules
Industry: Biotech

Drug pipeline

10 assets

LTX-002

9 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Leal Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Leal Therapeutics.

Explore the full profile